Latest RMD News

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payment to Australian CDI holders, impacting the Australian dollar amount payable per share. The dividend remains unfranked and subject to US withholding tax, with a reduced rate available under the US-Australia tax treaty.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

Small caps did the heavy lifting this week, led by two big discovery stories in resources. Funding raises and takeover moves kept attention on who can pay for the next step, not just promise it.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Resmed Inc. posted robust Q2 FY2026 results, with revenue climbing 11% to $1.4 billion and a 16% rise in non-GAAP earnings per share, underpinned by strong global demand and operational efficiencies.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payable to ASX CDI holders, impacting the Australian dollar amount investors will receive.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Resmed Inc. kicked off fiscal 2026 with robust 9% revenue growth and a notable 290 basis points gross margin expansion, signaling strong momentum in home healthcare innovation. The company also declared a $0.60 dividend and executed a $150 million share buyback, underscoring confidence in its strategic direction.

ResMed Inc has updated the foreign exchange rate for its forthcoming dividend payable to ASX-listed CDIs, setting the Australian dollar payout at 9.24 cents per CDI. This adjustment reflects the latest USD to AUD exchange rate and carries important tax implications for investors.